Showing 1851-1860 of 5631 results for "".
- Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Millionhttps://modernod.com/news/kala-pharmaceuticals-announces-financing-from-athyrium-capital-management-totaling-110-million/2479817/Kala Pharmaceuticals announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management LP, a healthcare focused investment firm. “We are pleased to be partnering with Athyrium and to have their support and confidence in Inveltys for the treatmen
- Switzerland Eye Research Institute Publishes Breakthrough Case Report Using Light Exposure and Nutraceuticals for Treating Retinal Degenerationhttps://modernod.com/news/switzerland-eye-research-institute-publishes-breakthrough-case-report-using-light-exposure-and-nutraceuticals-for-treating-retinal-degeneration/2480653/Roberto Pinelli, MD, CEO of the Switzerland Eye Research Institute, announced the publication of a breakthrough paper in Archives Italiennes de Biologie. The report can be found here:
- Bausch + Lomb Retina News, Eventshttps://modernod.com/news/bausch-lomb-retina-news-events/2480011/In advance of this week’s ASRS meeting, Bausch + Lomb Vice President and general manager of Surgical, Chuck Hess, distributed a customer letter to surgeons providing them an update on our progress in retina. The letter is below: Dear Eye Care Professional: At this time last y
- Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Developmenthttps://modernod.com/news/harrow-secures-5-year-strategic-agreement-for-triesence-and-announces-next-generation-development/2482696/Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid is FDA-approved for visualization during vitrectomy
- SpyGlass Pharma Unveils 1-Year Data of Its Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucomahttps://modernod.com/news/spyglass-pharma-unveils-1-year-data-of-its-drug-delivery-platform-implanted-during-routine-cataract-surgery-in-eyes-with-glaucoma/2482196/SpyGlass Pharma announced 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ IOL-based drug delivery platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation
- GALE Extension Study Shows Syfovre Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with GAhttps://modernod.com/news/gale-extension-study-shows-syfovre-continued-to-demonstrate-increasing-treatment-effects-over-3-years-in-patients-with-ga/2481943/Apellis Pharmaceuticals announced data from the GALE extension study following 3 years of continuous treatment with Syfovre (pegcetacoplan injection), the first FDA-approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data were rep
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression After 2 Yearshttps://modernod.com/news/coopervision-sightglass-vision-diffusion-optics-technology-demonstrates-significant-reduction-in-myopia-progression-after-two-years/2480328/CooperVision’s SightGlass Vision Business has revealed 2-year clinical study data for its Diffusion Optics Technology, which is designed to slow the progression of myopia in children.1 After 2 years, children who wore their Diffusion Optics Technology-enabled spectacles full
- Hydrus Microstent Now First MIGS Device With 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/Ivantis, developer of the novel Hydrus Microstent, announced the first release of 5-year follow-up data from its HORIZON pivotal trial. This milestone represents the longest continuous follow-up of a MIGS device pivotal trial. The 5-year HORIZON data demonstrated the Hydrus Microstent̵
- EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020https://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Data presented included: Statistically significant effi